PeptidePlaza
The Free Peptide Reference

Insulin Zinc, Extended

From PeptidePlaza, the free peptide reference · Entry #1219 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Insulin Zinc, Extended is a metabolic research peptide. Insulin Zinc, Extended is an insulin receptor agonist currently in Phase 2 clinical trials.

Insulin Zinc, Extended is a compound that functions as an agonist of the insulin receptor. It is currently undergoing investigation in Phase 2 clinical trials. Research related to this compound includes studies on insulin glargine, the hexokinase method, and the identification of indole-based activators of insulin degrading enzyme. The literature also features reviews on families of zinc metalloproteases.

1 Mechanism of action

Insulin receptor agonist (agonist)

Primary targets: Insulin receptor

2 Chemical and physical properties

Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsInsulin receptor

3 Research studies (8)

  1. Insulin glargine
    Drugs (2000)
  2. Hexokinase Method
    (2026)
  3. Inhibition of zDHHC7-driven protein S-palmitoylation prevents cognitive deficits in an experimental model of Alzheimer's disease
    Proceedings of the National Academy of Sciences of the United States of America (2024)
  4. Families of zinc metalloproteases
    FEBS letters (1994) · Review
  5. Identification of indole-based activators of insulin degrading enzyme
    European journal of medicinal chemistry (2022)
  6. Structural principles of insulin formulation and analog design: A century of innovation
    Molecular metabolism (2021) · Review
  7. The transcription factor Zfh1 acts as a wing-morph switch in planthoppers
    Nature communications (2022)
  8. Gli-similar proteins: their mechanisms of action, physiological functions, and roles in disease
    Vitamins and hormones (2012) · Review

4 Safety and risk profile

4.1 Regulatory status

Insulin Zinc, Extended is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

5 Frequently asked questions

What is Insulin Zinc, Extended?
Insulin Zinc, Extended is a compound classified as an insulin receptor agonist. It is currently in Phase 2 clinical trials, indicating it is undergoing further study for potential medical applications.
How does Insulin Zinc, Extended work?
Insulin Zinc, Extended works by acting as an agonist for the insulin receptor. This means it binds to and activates the insulin receptor, mimicking the effects of insulin in the body.
What is the regulatory status of Insulin Zinc, Extended?
Insulin Zinc, Extended is currently in Phase 2 clinical trials. This stage of development involves further testing to evaluate its efficacy and safety in a larger group of people.

6 References

  1. Insulin Zinc, Extended — molecule record ChEMBL. View source
  2. Insulin Zinc, Extended — published literature (51 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Insulin Zinc, Extended.

Insulin Glargineapproved

Also targets Insulin receptor

Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.

Insulin Aspartapproved

Also targets Insulin receptor

Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.

Insulin Lisproapproved

Also targets Insulin receptor

Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.

Insulin Degludecapproved

Also targets Insulin receptor

Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.

Insulin Detemirapproved

Also targets Insulin receptor

Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.

Insulin Zincapproved

Also targets Insulin receptor

Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.

7 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.